Nature Reviews Clinical Oncology最新文献

{"title":"Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?","authors":"Tim F Greten, Mitchell Ho","doi":"10.1038/s41571-026-01206-2","DOIUrl":"https://doi.org/10.1038/s41571-026-01206-2","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: Antibody–drug conjugates in gynaecological cancers: opportunities and challenges","authors":"Kathleen N. Moore, Oladapo O. Yeku, Brooke E. Howitt, Hagop Youssoufian, Joyce F. Liu","doi":"10.1038/s41571-026-01208-0","DOIUrl":"10.1038/s41571-026-01208-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"913-913"},"PeriodicalIF":94.6,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41571-026-01208-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary efficacy with daraxonrasib demonstrated in RAS-mutant NSCLC","authors":"Diana Romero","doi":"10.1038/s41571-026-01207-1","DOIUrl":"10.1038/s41571-026-01207-1","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"826-826"},"PeriodicalIF":94.6,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology","authors":"William Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza","doi":"10.1038/s41571-026-01205-3","DOIUrl":"10.1038/s41571-026-01205-3","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"913-913"},"PeriodicalIF":94.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41571-026-01205-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148922931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver resection improves survival in patients with locally advanced HCC","authors":"Peter Sidaway","doi":"10.1038/s41571-026-01202-6","DOIUrl":"10.1038/s41571-026-01202-6","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"825-825"},"PeriodicalIF":94.6,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology","authors":"William Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza","doi":"10.1038/s41571-026-01198-z","DOIUrl":"10.1038/s41571-026-01198-z","url":null,"abstract":"Oncolytic virotherapy has evolved from a platform predicated on lysis of cancer cells into a sophisticated system for intratumoural immune reprogramming; the prevailing ‘cold-to-hot’ paradigm captures only part of this potential. A fundamental limitation shared by immune checkpoint inhibitors (ICIs) and early-generation oncolytic viruses (OVs) is a reliance on pre-existing tumour-specific T cells (TSTs), which presents an immunological ceiling that constrains antitumour activity — given that these agents have a limited capacity to generate TSTs de novo. Next-generation OVs overcome this constraint by functioning as agents for antigen-agnostic in situ cancer vaccination: intratumoural infection triggers immunogenic cell death, releasing potentially the full cancer proteome under pathogen-associated and/or damage-associated molecular pattern adjuvant conditions, thereby driving T cell priming against patient-specific neoantigens. In this Perspective, we delineate four pillars for the development of next-generation OVs. First, intratumoural vaccination as immunological ignition, with initial clinical data demonstrating T cell clonotype broadening, abscopal tumour regression and survival benefit in patients with ICI-refractory disease. Second, optimized payload-driven immune priming to hyperactivate antigen-presenting cells. Third, revised efficacy evaluation and end points using response criteria as well as novel biological correlates that better capture delayed and abscopal immune-mediated tumour control. Fourth, OV as the foundational immuno-oncology platform: according to the ‘triple-A’ framework encompassing admission, availability and activation of TSTs, next-generation, payload-engineered OVs uniquely satisfy all prerequisites for antitumour immunity simultaneously, with evidence from clinical trials of such agents supporting an ‘OV-prime, ICI-amplify’ strategy. Notably, OVs are systemic immune-reprogramming platforms that are delivered locally, not local therapies with incidental systemic effects. The development of diverse immunotherapeutic modalities has revolutionized the treatment of cancer but the effectiveness of these therapies remains restricted by fundamental mechanistic limitations relating to the generation of tumour-specific T cells, and their activation and/or access into the tumour microenvironment. In this Perspective, the authors position oncolytic viruses as a foundational immuno-oncology platform for systemic immune reprogramming to simultaneously overcome these availability, activation and admission barriers, and delineate four pillars for the development of a new generation of oncolytic virotherapies.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"893-912"},"PeriodicalIF":94.6,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC","authors":"Peter Sidaway","doi":"10.1038/s41571-026-01200-8","DOIUrl":"10.1038/s41571-026-01200-8","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"825-825"},"PeriodicalIF":94.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems.","authors":"Monireh Sadat Seyyedsalehi, Paolo Boffetta","doi":"10.1038/s41571-026-01199-y","DOIUrl":"https://doi.org/10.1038/s41571-026-01199-y","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":94.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148831049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the landscape of targetable alterations in patients with glioblastoma","authors":"Elisa Aquilanti, Mehdi Touat, Pim French, Antonio Iavarone, David Capper, Marjolein Geurts, Rifaquat Rahman, Roel Verhaak, Matthias Preusser, Martin van den Bent, Patrick Y. Wen","doi":"10.1038/s41571-026-01190-7","DOIUrl":"10.1038/s41571-026-01190-7","url":null,"abstract":"Glioblastomas remain the most lethal primary brain tumour in adults, with targeted therapies delivering only limited benefit despite deep molecular characterization. Several targeted drugs have received regulatory approval for low-grade gliomas, although progress in glioblastomas remains constrained by, among other aspects, extensive intratumoural heterogeneity, pathway redundancy, cellular plasticity and limited drug delivery to the central nervous system. Some of these challenges might be mitigated through strategies that enhance blood–brain penetration, including focused ultrasonography, convection-enhanced delivery, efflux avoidance and chemical modifications. Improved tumour profiling through multiregional sampling, prioritization of truncal dependencies and the development of novel therapeutic modalities, such as antibody–drug conjugates and theranostics, might also further improve outcomes. In this Review, we summarize the therapeutic landscape of targeted therapies in glioblastomas, spanning major target classes including receptor tyrosine kinases, intracellular signalling proteins, cell-cycle dysregulation and synthetic-lethal vulnerabilities. We also examine emerging strategies targeting genome integrity and telomeres, epigenetic modulators, and tumour–neural circuitry. Furthermore, we highlight tumour heterogeneity and extrachromosomal DNA dynamics as key drivers of oncogene amplification and therapeutic resistance as well as the roles of novel clinical trial designs and liquid biopsy-based monitoring strategies. Lastly, we discuss pathway-based glioblastoma classification and master kinase mapping as methods for aligning drugs with functional tumour states. Despite considerable progress in other cancer types, progress with the development of targeted therapies for patients with glioblastoma has remained limited, despite considerable research effort. In this Review, the authors summarize the various attempts to develop effective targeted therapies for patients with glioblastoma, including some of the challenges that have likely impaired progress thus far. The authors also highlight novel therapies, clinical trial designs and research directions that have been informed by the shortcomings of previous research efforts, all of which might eventually lead to improved outcomes for patients.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"849-871"},"PeriodicalIF":94.6,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma","authors":"Fen Saj, Lipika Goyal","doi":"10.1038/s41571-026-01194-3","DOIUrl":"10.1038/s41571-026-01194-3","url":null,"abstract":"The phase III FIGHT-302 trial demonstrated that the FGFR inhibitor pemigatinib improves progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage FGFR2-rearranged cholangiocarcinoma. However, the trial accrued slowly and closed early after chemoimmunotherapy became the new standard of care. FIGHT-302, alongside two similarly terminated trials, highlights the need for innovative trial designs and flexible regulatory frameworks to evaluate therapies in rare, biomarker-defined populations.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"23 11","pages":"829-830"},"PeriodicalIF":94.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}